10x Genomics Inc - Ordinary Shares - Class A
TXG
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.72B
Close$
$14.27
83% downside
Current Fair Value
83% downsideOvervalued by 83% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.72 Billion |
|---|---|
| Enterprise Value | $9.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.35 |
| Beta | 2.08 |
| Outstanding Shares | 129,984,169 |
Return
| Return on Equity | -9.10% |
|---|---|
| Return on Assets | -7.29% |
| Return on Invested Capital | -9.60% |
Valuation & Multiples
| P/E Ratio | -129.83 |
|---|---|
| PEG | 85.46 |
| Price to Sales | 21.03 |
| Price to Book Ratio | 14.02 |
| Enterprise Value to Revenue | 15.12 |
| Enterprise Value to EBIT | -106.6 |
| Enterprise Value to Net Income | -125 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$146.67 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$147.70 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1653▲ 10.23% |
|---|---|
| Total Calls | 613,600▼ 41.22% |
| Total Puts | 101,400▲ 54.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.69%▲ 2.06% |
|---|---|
| Total Invested | $4.96B▲ 86.77% |
| Investors Holding | 403▲ 63.00% |
ESG Score
No data
About 10x Genomics Inc
CEO: Serge Saxonov